tbuckley/cabot-search huggingface dataset:
Involvement of the immunoregulator MZB1 in progression of gastric cancer
Authors: Y. Tanaka, M. Kanda, C. Tanaka, D. Kobayashi, H. Tanaka, H. Takami, M. Hayashi, N. Iwata, Y. Niwa, S. Yamada, G. Nakayama, H. Sugimoto, M. Koike, M. Fujiwara, Y. Kodera
Journal: Annals of Oncology (2017)
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
Authors: P. Nuciforo, T. Pascual, J. Cortés, A. Llombart-Cussac, R. Fasani, L. Paré, M. Oliveira, P. Galvan, N. Martínez, B. Bermejo, M. Vidal, S. Pernas, R. López, M. Muñoz, I. Garau, L. Manso, J. Alarcón, E. Martínez, V. Rodrik-Outmezguine, J.C. Brase, P. Villagrasa, A. Prat, E. Holgado
Journal: Annals of Oncology (2017)
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
Authors: Luca Fania, Adele Salemme, Alessia Provini, Gianluca Pagnanelli, Maria Chiara Collina, Damiano Abeni, Biagio Didona, Giovanni Di Zenzo, Cinzia Mazzanti
Journal: Journal of the American Academy of Dermatology (2017)
US health secretary quits over improper use of aircraft
Authors: Owen Dyer
Journal: BMJ (2017)

The Trump administration must find a new secretary of health and human services after Tom Price resigned over his extravagant use of charter and military aircraft.

The news website Politico revealed that Price had spent over $400 000 (£300 000; €340 000) of taxpayers’ money on private charters. Some flew him to hastily arranged small official events in destinations where he had vacation property or relatives, which he then also visited.

The former orthopedic surgeon from Georgia at first rebuffed the criticism, claiming that his busy schedule necessitated charter travel. But Donald Trump, who also criticized the flying habits of three cabinet officials, offered Price little support, telling reporters when questioned, “I’m not happy about it, and I let him know it.”

Price then promised to repay $51 887.31, the cost of his own seat on the charter flights. He vowed to take no more charters and …
GW28-e1146 Effectiveness and safety of anticoagulation therapy with dabigatran etexilate in patients undergoing catheter ablation and cardioversion procedures for atrial fibrillation
Authors: Yingming Ding, Wang Zulu, Yang Guitang, Liang Ming, Jin Zhiqing, Sun Mingyu, Liang Yanchun, Han Yaling, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Breast Cancer Screening in Denmark
Authors: Tony H.H. Chen, Stephen W. Duffy
Journal: Annals of Internal Medicine (2017)

Letters3 October 2017Breast Cancer Screening in DenmarkTony H.H. Chen, PhD and Stephen W. Duffy, BSc, MSc, CStatTony H.H. Chen, PhDFrom Queen Mary University of London, London, United Kingdom.Search for more papers by this author and Stephen W. Duffy, BSc, MSc, CStatFrom Queen Mary University of London, London, United Kingdom.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0267 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Jørgensen and colleagues (1) compare changes over time, up to 2010, in the incidence of large and small breast tumors between areas of Denmark that did and did not have screening programs. They conclude that screening had no effect on the incidence of large tumors and that there is substantial overdiagnosis. However, the data presented in this article indicate the opposite conclusions.Table 2 of the article clearly shows that, in women aged 50 to 69 years, incidence of large tumors increased by 46% in nonscreening areas but decreased by 4% in screening areas. This finding indicates ...Reference1. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. Ann Intern Med. 2017;166:313-23. [PMID: 28114661]. doi:10.7326/M16-0270 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Queen Mary University of London, London, United Kingdom.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0267. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBreast Cancer Screening in Denmark Karsten Juhl Jørgensen , Peter C. Gøtzsche , Mette Kalager , and Per-Henrik Zahl Breast Cancer Screening in Denmark Changjun Wang , Yidong Zhou , Feng Mao , Yan Lin , and Qiang Sun Breast Cancer Screening in Denmark Sameer Bhargava , Kaitlyn Tsuruda , and Solveig Hofvind Breast Cancer Screening in Denmark Karsten Juhl Jørgensen , Peter C. Gøtzsche , Mette Kalager , and Per-Henrik Zahl Metrics 3 October 2017Volume 167, Issue 7Page: 523-524KeywordsAge groupsBreast cancerBreast cancer screeningCancer detection and diagnosisCancer preventionCancer risk factorsCancer screeningConflicts of interestDisclosureRisk ratio ePublished: 3 October 2017 Issue Published: 3 October 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte‐predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation‐lymphoma working party
Authors: Saad Akhtar, Silvia Montoto, Ariane Boumendil, Herve Finel, Tamas Masszi, Pavel Jindra, Damir Nemet, Stephan Fuhrmann, Yves Beguin, Luca Castagna, Felicetto Ferrara, Saveria Capria, Ram Malladi, Jose Maria Moraleda, Adrian Bloor, Hervé Ghesquières, Julia Meissner, Anna Sureda, Peter Dreger
Journal: American Journal of Hematology (2017)

Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy. NLPHL transformed to diffuse large B cell lymphoma were excluded. Sixty patients (83% male; median age 40 years) met the eligibility criteria. The median time between diagnosis and transplant was 21 months (IQR 13-58), and the median number of prior treatment lines was 2 (range 1-5), including rituximab in 63% of the patients. At auto-SCT, 62% of the patients were in complete remission (CR) and 38% in partial remission. Seventy-two percent of the patients received BEAM as high-dose therapy. With a median follow-up of 56 months (range 3-105), 5-year progression-free and overall survival (OS) were 66% and 87%, respectively. Univariate comparisons considering age, time from diagnosis to transplant, prior chemotherapy lines, and prior rituximab use failed to identify significant predictors for any survival endpoint except for being in CR at the time of auto-SCT (vs PR, P = .049) for OS. Auto-SCT in patients with relapsed/refractory NLPHL who are sensitive to salvage therapy gives excellent disease control and long-term survival independent of the time interval between diagnosis and transplant.
Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)
Authors: Y. Mori, N. Suzuki, T. Nagasaka, H. Tanioka, Y. Iwamoto, Y. Neki, T. Yamatsuji, M. Kobayashi, M. Nakajima, Y. Ojima, S. Ikeda, K. Kawamoto, K. Shinozaki, A. Tsuji, T. Hinoi, Y. Yamaguchi, K. Yamashita, M. Shimokawa, M. Okajima, S. Hazama
Journal: Annals of Oncology (2017)
Cell-based breast cancer risk stratification based on DNA methylation in fine needle aspiration samples
Authors: D. Euhus, D. Bu, S. Milchgrub, A. M. Leitch, C. M. Lewis
Journal: Journal of Clinical Oncology (2007)

1508 Background: Tumor suppressor gene (TSG) methylation is identified in nearly all breast cancers, but rarely in histologically normal breast tissue from wonen unaffected with breast cancer. Its occurrence in high risk preneoplasia and in benign breast tissue adjacent to breast cancer suggests that it may represent a high risk field change that could be exploited for cell-based breast cancer risk stratification. Methods: TSG methylation was measured by quantitative methylation-specific real time PCR in 53 breast tumor fine needle aspiration (FNA) biopsies, 84 cellular random periareolar FNAs (RP-FNA) ipsilateral or contralateral to these cancers, 36 cellular RP- FNAs from unaffected women at high risk for breast cancer by the Gail model, and 95 cellular RP-FNAs from unaffected women at lower risk by the Gail model. Results: The breast tumors showed a high frequency of TSG methylation: RASSF1A 80%, HIN-1 65%, Cyclin D2 60%, RAR-β2 53%, and APC 47%. In general, RP-FNA samples from cancer patients and Gail high risk patients showed a greater frequency of methylation than samples from Gail lower risk patients: RASSF1A 43% vs. 21%, P = 0.001, HIN-1 32% vs. 20%, P = 0.05; Cyclin D2 18% vs. 9%, P = 0.10; RAR-β2 21% vs. 18%, P = 0.68; and APC 25% vs. 16%, P = 0.17. Twelve of 215 RP-FNA samples (5%) showed very high levels of methylation (&gt;10% methylation for two or more genes). Only two of these samples were from women classified as lower risk by the Gail model. Methylation frequencies were entirely independent of cell yields but the frequency of RASSF1A methylation increased with increasing Masood scores (P = 0.05). Methylation of RASSF1A in one breast was highly predictive of RASSF1A methylation in the opposite breast (P &lt; 0.0001). Conclusions: TSG methylation appears to be a breast cancer risk-associated field change that can be quantified in RP-FNA samples. RASSF1A methylation occurs frequently in benign breast epithelium, provides reasonable discrimination between high and lower risk breasts (O.R. = 2.0), is related to cytological atypia, and may be an early marker of a methylator phenotype. Quantification of TSG methylation in RP-FNA samples may provide a valuable surrogate endpoint biomarker for Phase II prevention trials. No significant financial relationships to disclose.
Hacia una profilaxis estándar postexposición al VIH para el personal sanitario en Europa
Authors: V Puro, S Cicalini, G De Carli, F Soldani, G Ippolito
Journal: Eurosurveillance (2004)

La profilaxis antiretroviral despues de una exposicion ocupacional al VIH (PEP) en personal sanitario se utiliza ampliamente en Europa, pero no de manera homogenea. Un grupo de expertos, financiado por la Comision Europea, ha formulado una serie de recomendaciones. 
Una vez decidida la conveniencia de iniciar la PEP, por las caracteristicas de la exposicion, el tratamiento debe comenzar lo antes posible. Si han pasado mas de 72 horas desde la exposicion, la PEP se desaconseja. La profilaxis deberia iniciarse de forma habitual con una de las combinaciones de tres antiretrovirales recomendadas para el tratamiento de pacientes infectados por VIH, siendo preferible la utilizacion de dos clases de antiretrovirales. Los antecedentes de tratamiento del paciente fuente deben buscarse en su historia farmacologica. Todos los expuestos tienen que recibir consejo, ayuda psicologica y se deben realizar pruebas de anticuerpos al VIH y una evaluacion clinica inmediatamente despues de la exposicion, a las 6-8 semanas y, al menos, a los 6 meses. Un seguimiento clinico y analitico tendria que hacerse entre la primera y segunda semana despues de la exposicion, ya que la adherencia al tratamiento y la tolerancia pueden producir efectos secundarios y toxicidad potencial. No se recomiendan pruebas de resistencia de rutina a los antiretrovirales en el paciente fuente, ni aislamiento del virus en el personal sanitario expuesto.
Rubella control in Italy
Authors: M L Ciofi Degli Atti, A Filia, M G Revello, W Buffolano, S Salmaso
Journal: Eurosurveillance (2004)

In Italy, rubella vaccination has been recommended since 1972 for pre-adolescent girls, and since the early 1990s for all children in the second year of life. Nevertheless, coverage in children from 12 to 24 months of age is suboptimal (i.e., 56% in 1998, 78% in 2003), with wide variations among regions. As a result, rubella is still circulating in Italy, and in 1996 the percentage of women susceptible to rubella between 15 and 39 years of age was >5%. Congenital rubella syndrome (CRS) was a notifiable disease between 1987 and 1991, with a range of 8-76 cases reported annually. Since 1992, national incidence data are no longer available, but local reports show that CRS cases are still occurring. Nationwide, coordinated and uniform actions are needed to control CRS effectively. For this reason, the National Plan for the Elimination of Measles and of Congenital Rubella has recently been launched. This plan includes strategies aimed at increasing MMR vaccination coverage in children and specific control measures for congenital rubella control, i.e., improving the vaccination of susceptible women of childbearing age, and reintroducing national surveillance of CRS.
Use of everolimus in advanced hormone receptor positive metastatic breast cancer in a multicenter national observational study
Authors: A. Lardy-Cleaud, P. Cottu, S. Frank, O. Le Saux, S. Chabaud, D. Parent, B. Pistilli, M. Debled, A. Mailliez, C. Veyret, T. Petit, L. Uwer, S. Guiu, M. Ung, E. Chamorey, P. Arveux, T. Guesmia, P. Augereau, G. Simon, T. Bachelot
Journal: Annals of Oncology (2017)
A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
Authors: Danny Rischin, Michael J. Boyer, Christina E. Brzezniak, A. Dimitrios Colevas, Robert Charles Doebele, Jill Gilbert, Barbara Gitlitz, Saad A. Khan, Ranee Mehra, Tanguy Y. Seiwert, Stew Kroll, Tillman E. Pearce, Stephen V. Liu
Journal: Journal of Clinical Oncology (2016)

TPS6105 Background: R/M SCCHN/SCCS have a poor prognosis. Molecularly targeted EGFR therapies provide some clinical benefit but are limited by systemic on-target side effects such as rash and diarrhea. SCCHN is a hypoxic tumor type. The presence of hypoxia has been shown to be associated with poorer outcomes and shorter survival. Additionally, tumor hypoxia upregulates WT EGFR signalling through several HIF-dependent mechanisms. TRLX is a hypoxia-activated prodrug that releases an irreversible pan-ErbB TKI targeting WT EGFR, mutant EGFR and HER2. Hypoxic tumor targeting using TRLX may allow a greater therapeutic and less dose-limiting systemic toxicity than seen with current EGFR TKIs. A Phase 1 study in pts with advanced solid tumors established the MTD of TRLX administered as a 1-hour weekly IV infusion at 150 mg/m2. The most common treatment-related adverse events were dose-dependent and included rash, QT prolongation, nausea, infusion reaction, vomiting, diarrhea and fatigue. Methods: A multicenter Phase 2 trial was initiated to evaluate the safety and activity of single-agent TRLX in pts with R/M SCCHN or SCCS (NCT02449681). The primary endpoint is RECIST 1.1 response rate. Secondary endpoints include PFS, duration of response, OS, PK and safety, as well as hypoxia PET imaging with [18F]HX-4 and molecular analyses of tumor tissue and plasma for biomarkers that may be associated with tumor response (including exome and mRNA analysis, EGFR-GRB2 proximity-ligand assay, and Veristrat plasma assay). Up to 68 pts will be enrolled with at least 10 pts in each of three disease specific groups (P16-positive oropharyngeal carcinoma, P16-negative SCCHN, SCCS). Key eligibility criteria include measureable disease according to RECIST 1.1 and ECOG performance status 0-2. Prior systemic therapy is not required for SCCS. Prior EGFR TKI therapy is not allowed; prior EGFR antibody therapy is allowed. TRLX (150 mg/m2) is administered by IV infusion over 60 minutes on Days 1, 8, 15 and 22 of a 28-day cycle. The study design incorporates a Simon two-stage design (alpha = 0.05; beta = 0.20) based on response rate. Recruitment is ongoing. Clinical trial information: NCT02449681.
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
Authors: Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu Reddy, Lindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, Hema Sundar
Journal: Journal of the National Comprehensive Cancer Network (2017)

Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.
GW28-e0140 Knockout of Small Ubiquitin-Like Modifier 1 Protects the Mice from Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction
Authors: Liuying Zheng, Guoxing Zuo, Huaxin Sheng, Kuan Wang, Wei Yang, Wulf Paschen, Xinping Du
Journal: Journal of the American College of Cardiology (2017)
Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study
Authors: Stephan A. Grupp, Angela R. Smith, Brandon M. Triplett, Nancy A. Kernan, Joseph H. Antin, Leslie Lehmann, Wei Liang, Robin Hume, William Tappe, Paul G. Richardson
Journal: Blood (2016)
Dynamic changes in levels of gene mutations using circulating tumor DNA (ctDNA) and efficacy of 1st-line modified (m)-FOLFOXIRI plus bevacizumab (bev) for metastatic colorectal cancer (mCRC) harboring RAS mutation (mt) (JACCRO CC-11)
Authors: Y. Sunakawa, T. Sekikawa, J. Usher, H. Satake, Y. Jaimes, Y. Miyamoto, M. Nakamura, H. Nakayama, K. Kazama, A. Takagane, A. Makiyama, K. Kobayashi, Y. Kubota, M. Mori, M. Kotaka, M. Takeuchi, M. Fujii, K. Danenberg, H-J. Lenz, W. Ichikawa
Journal: Annals of Oncology (2017)
Comprehensive detection of ctDNA variants at 0.1% allelic frequency using a broad targeted NGS panel for liquid biopsy research.
Authors: Richard Chien, Dumitru Brinza, Jian Gu, Dalia Dhingra, Kunal Banjara, Yanchun Li, Varun Bagai, Jeoffrey Schageman, Efren Ballesteros-Villagrana, Ruchi Chaudhary, Khalid Hanif, Janice Au-Young, Fiona Hyland, Kelli Bramlett
Journal: Journal of Clinical Oncology (2017)

e23065 Background: Advances in non-invasive tumor biomarker research have shown that tumor cells release fragments of DNA called circulating tumor DNA (ctDNA) into peripheral blood. Somatic mutations representing the tumors could be successfully detected from isolated ctDNA, providing new potential for tumor sample assessment in addition to traditional tissue biopsy methods. However, the low amount of ctDNA in the blood, which can be less than 1% allelic frequency, presents significant challenges for reliable variant detection with NGS assays. Improvement of sequencing accuracy at low allelic frequency is a critical factor in the implementation of NGS in ctDNA liquid biopsy research. Methods: We demonstrate the technical feasibility for a sample-to-variant NGS workflow that utilizes a broad multi-gene panel to survey a comprehensive list of variants relevant to multiple tumor types for liquid biopsy research. The method includes novel library preparation and analysis reporting for Ion Torrent™ sequencing platforms. 20ng of input cell-free DNA was subjected to the library generation protocol. Prepared libraries were templated on Ion Chef™ and sequenced on Ion S5™. Results: We successfully optimized an NGS workflow that enables the simultaneous examination of more than 360 driver and resistance hotspot mutations in a single-pool assay panel, achieving high sensitivity and specificity with limit of detection at 0.1% allelic frequency. The targeted regions span genes and variants relevant to multiple tumor types for comprehensive variant detection across high-value content reviewed by industry experts and researchers. Sequencing on the Ion S5™ delivered &gt; 95% on-target reads and uniform amplification across targeted regions with deep sequencing depth ( &gt; 40,000x). The workflow is compatible with single or multiple pooled samples on Ion Torrent™ sequencing chips. Conclusions: We demonstrate the ability to accurately detect high-value variants implicated in multiple tumors at 0.1% allelic frequency on Ion Torrent™ NGS. (For Research Use Only. Not for use in diagnostic procedures.)
Endoscopic removal of a proximally migrated biliary stent using a novel gooseneck snare: the “EndoCowboy”
Authors: Tadahisa Inoue, Rena Kitano, Yuji Kobayashi, Norimitsu Ishii, Kiyoaki Ito, Masashi Yoneda
Journal: Endoscopy (2017)

Proximal migration often occurs as an adverse event of biliary stent placement, with a reported migration rate of 3.1 % – 4.9 % [1]. Although various techniques have been reported for endoscopic removal of proximally migrated biliary stents, the procedure is still technically demanding and time-consuming, and occasionally unsuccessful [2] [3] [4]. We describe a useful technique for endoscopic removal of a proximally migrated biliary stent using a novel gooseneck snare ([Fig. 1]).
Dual CDK 4/6 inhibitor demonstrates potent antitumor efficacy in vitro and in vivo against esophageal adenocarcinoma
Authors: A.N. Omstead, J.E. Kosovec, M.J. Biedka, R.W.W. Biederman, R.J. Kelly, A.H. Zaidi, B.A. Jobe
Journal: Annals of Oncology (2017)
GW28-e1193 The GRACE risk score has better prediction accuracy for new-onset atrial fibrillation than CHA2DS2-VASc score in patients with ST-segment elevation myocardial infarction
Authors: Jiachen Luo, Liming Dai, Jianming Li, Jinlong Zhao, Yong Li, Guli Maihe, Xiaoming Qin, Hongqiang Li, Baoxin Liu, Yidong Wei
Journal: Journal of the American College of Cardiology (2017)
EGFR mutation detection in plasma cell-free DNA correlates with clinical outcomes in non-small cell lung cancer
Authors: J. Shi, J. Mong, T.M. Chin, Y.H. Lim, W.L. Tan, C.K. Toh, H.S. Tan, S-W. Wong, A. Tee, D. Chan, K. Wong, S. Yeap, L. Ngo, Y-O. Tan, M-H. Tan
Journal: Annals of Oncology (2017)
Detailed Clinical, Immunological and Molecular Analysis of NOTCH1, SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals
Authors: Maciej Putowski, Marta Podgórniak, Marta Piróg, Joanna Knap, Jacek Zawislak, Joanna Zaleska, Ewelina Zakrzewska, Joanna Purkot, Agnieszka Karczmarczyk, Paulina Wlasiuk, Waldemar Tomczak, Edyta Cichocka, Edyta Subocz, Janusz Halka, Daria Zawirska, Witold Jeleniewicz, Andrzej Stepulak, Tomasz Stoklosa, Krzysztof Giannopoulos
Journal: Blood (2016)
Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
Authors: S-E. Al-Batran, C. Pauligk, N. Homann, H. Schmalenberg, H-G. Kopp, G.M. Haag, K. Luley, G. Folprecht, S. Probst, P. Thuss-Patience, J. Trojan, M. Koenigsmann, U. Lindig, M. Pohl, S. Kasper, M. Möhler, T. Goetze, M. Schuler, E. Jaeger, R.D. Hofheinz
Journal: Annals of Oncology (2017)